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Background: Nemaline myopathy (NM) is a rare genetic muscle disorder, but one of the most common among
the congenital myopathies. NM is caused by mutations in at least nine genes: Nebulin (NEB), α-actin (ACTA1),
α-tropomyosin (TPM3), β-tropomyosin (TPM2), troponin T (TNNT1), cofilin-2 (CFL2), Kelch repeat and BTB (POZ)
domain-containing 13 (KBTBD13), and Kelch-like family members 40 and 41 (KLHL40 and KLHL41). Nebulin is a giant
(600 to 900 kDa) filamentous protein constituting part of the skeletal muscle thin filament. Around 90% of the
primary structure of nebulin is composed of approximately 35-residue α-helical domains, which form super repeats
that bind actin with high affinity. Each super repeat has been proposed to harbor one tropomyosin-binding site.
Methods: We produced four wild-type (WT) nebulin super repeats (S9, S14, S18, and S22), 283 to 347 amino acids
long, and five corresponding repeats with a patient mutation included: three missense mutations (p.Glu2431Lys,
p.Ser6366Ile, and p.Thr7382Pro) and two in-frame deletions (p.Arg2478_Asp2512del and p.Val3924_Asn3929del). We
performed F-actin and tropomyosin-binding experiments for the nebulin super repeats, using co-sedimentation and
GST (glutathione-S-transferase) pull-down assays. We also used the GST pull-down assay to test the affinity of WT
nebulin super repeats for WT α- and β–tropomyosin, and for β-tropomyosin with six patient mutations: p.Lys7del,
p.Glu41Lys, p.Lys49del, p.Glu117Lys, p.Glu139del and p.Gln147Pro.
Results: WT nebulin was shown to interact with actin and tropomyosin. Both the nebulin super repeats containing
the p.Glu2431Lys mutation and nebulin super repeats lacking exon 55 (p.Arg2478_Asp2512del) showed weak
affinity for F-actin compared with WT fragments. Super repeats containing the p.Ser6366Ile mutation showed strong
affinity for actin. When tested for tropomyosin affinity, super repeats containing the p.Glu2431Lys mutation showed
stronger binding than WT proteins to tropomyosin, and the super repeat containing the p.Thr7382Pro mutation
showed weaker binding than WT proteins to tropomyosin. Super repeats containing the deletion p.
Val3924_Asn3929del showed similar affinity for actin and tropomyosin as that seen with WT super repeats. Of the
tropomyosin mutations, only p.Glu41Lys showed weaker affinity for nebulin (super repeat 18).
Conclusions: We demonstrate for the first time the existence of direct tropomyosin-nebulin interactions in vitro,
and show that nebulin interactions with actin and tropomyosin are altered by disease-causing mutations in nebulin
and tropomyosin.
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Nemaline myopathy (NM) is a neuromuscular disorder
characterized by muscle dysfunction and the presence of
nemaline bodies (rods) in the muscle fibers. The rods
are composed of thin filament and Z-disk proteins [1-4].
To date, nine different causative genes have been identi-
fied for NM: nebulin (NEB), skeletal muscle α-actin
(ACTA1), slow α-tropomyosin (TPM3), β-tropomyosin
(TPM2), slow troponin T (TNNT), cofilin-2 (CFL2), Kelch
repeat and BTB (POZ) domain-containing 13 (KBTBD13;
a member of the BTB/Kelch protein family), and Kelch-
like family members 40 and 41 (KLHL40, KLHL41) [5-13].
Mutations in NEB and ACTA1 are the most common
causes of NM. In addition to NM, mutations in NEB cause
distal nebulin myopathy with no or almost no nemaline
bodies, a condition so far described only in Finland [14],
distal myopathy with nemaline bodies (distal nemaline
myopathy) [15], and rare cases of core-rod myopathy [16].
A rapidly growing number of mutations in the human
NEB gene have been identified as a common cause of
NM. These NEB mutations include frameshifts, prema-
ture stop codons, splice-site mutations, large in-frame
deletions, and missense mutations [6,17-19]. The muta-
tions cause both mild and severe forms of NM, although
the typical congenital form appears to be the most com-
mon, which usually results only in slowly progressive
disease [1,2]. Homozygous missense mutations in NEB
have been found to cause distal nebulin myopathy [14],
and NEB compound heterozygous mutations may result
in core-rod myopathy [16].
Nebulin is a giant (600 to 900 kDa), thin-filament, actin-
binding protein, and the gene comprises a total of 183
exons, of which at least 17 are alternatively spliced, produ-
cing hundreds of different NEB isoforms [20]. A major
stretch of nebulin consists of repetitive modules, 30 to 35
amino acids (aa) long, called simple repeats [21]. Most
of these simple repeats are arranged into seven-module
super repeats. Each simple repeat has a predicted α-helical
secondary structure, and an SDXXYK motif that serves as
an actin-binding site [22,23]. A second motif, WLKGIGW,
is present once in each super repeat, and is thought to
serve as a tropomyosin-binding site [21]. The longest iso-
forms of nebulin bind as many as 239 actin monomers,
and are thought to act as molecular rulers, defining thin-
filament lengths, especially specifying minimum lengths
of the filaments to optimize thin/-thick filament overlap
and force production [24-26]. Apart from thin-filament
regulation, the structural roles of nebulin extend to main-
taining intermyofibrillar connectivity through interaction
with desmin [27] and setting physiological Z-disk widths
[24,28]. Knockout NebΔExon55 mice show impaired regula-
tion of contraction, which appears as marked changes in
cross-bridge cycling kinetics and a reduction in the cal-
cium sensitivity of force generation [29].Biochemical studies have shown that isolated nebulin
super repeats bind actin with high affinity [30]. Further-
more, a nebulette repeat 167 aa long, consisting of five
nebulin-like repeats approximately 35 aa long, was shown
to interact with actin, tropomyosin, and the troponin
complex [31]. This fragment shows the highest homology
to nebulin C-terminal simple repeats outside the super re-
peat region of nebulin. During muscle contraction, tropo-
myosin moves between different binding sites on the actin
filament, allowing actin-myosin interactions [32]. It also
appears that nebulin has several binding sites on actin,
suggesting that nebulin acts in concert with tropomyosin
during muscle contraction [32].
The successful isolation of the nebulin protein for the
first time [33], and the generation of knockout mouse
models [24,29,34] have helped elucidate the function of
this giant molecule. Because of the enormous size of
nebulin, functional studies of full-length nebulin are dif-
ficult. Hence, we opted for studying protein domains
(super repeats) containing mutations known to cause
NM (Figure 1). Mutations in all the selected super re-
peats have been reported to cause NM or distal myop-
athy (Table 1).
We produced four wild-type (WT) nebulin super repeats
(283 to 347 aa long) and five corresponding mutants:
three missense mutations (p.Glu2431Lys, p.Ser6366Ile,
and p.Thr7382Pro) and two in-frame deletions (p.Arg2478_
Asp2512del and p.Val3924_Asn3929del) (Table 1, Figure 1).
The p.Arg2478_Asp2512del (2.5 kb deletion including
exon 55) is a founder mutation in the Ashkenazi Jewish
population. The missense mutations p.Ser6366Ile and
p.Thr7382Pro are founder mutations in the Finnish popu-
lation [14,18]. We performed F-actin and tropomyosin-
binding experiments for the nebulin super repeats, using
co-sedimentation and GST-pull-down assays in order to
elucidate the pathogenetic mechanisms by which the mu-
tations exert their effects.
Methods
RNA isolation and RT-PCR
Total RNA was isolated from human vastus lateralis
(VL) muscles, using the RNeasy Fibrous Tissue Mini Kit
(Qiagen, Venlo, The Netherlands). cDNA was synthe-
sized from 2 μg of total RNA using the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA); 2 μl of template were used per
20 μl PCR reaction. All PCR reagents were from Thermo
Scientific (Waltham, MA, USA). The amplifications were
performed using Phusion High-Fidelity DNA polymer-
ase, and PCR products were cloned into pCRBluntII-
TOPO (Invitrogen, Carlsbad, CA, USA). For all nebulin
exon amplifications, after initial heating at 98°C for 1 mi-
nute, 30 cycles of denaturation at 98°C for 10 seconds,
annealing at 59°C for 30 seconds, and extension at 72°C
Figure 1 Nebulin and β-tropomyosin mutations studied. (A) The nebulin protein structure and the location of the mutations. The upper
part of the figure shows a schematic presentation of the nebulin protein structure and its known protein interaction partners. The lower
part of the figure shows a detailed view of the super repeats included in the study (S9, S14, S18, and S22), and the location of the mutations
(arrows) and tropomyosin-binding sites (X) in the super repeats. (B) Purified GST (glutathione-S-transferase)-nebulin and tropomyosin.
GST-nebulin domains were produced in the Escherichia coli strain BL21 (upper panel), and the α-tropomyosins (Tm3) and β-tropomyosins
(Tm2) in insect cells (lower panel). The proteins were purified, run in a SDS-PAGE gel, and stained with Coomassie Blue. The β-tropomyosin
mutations p.K49del and p.E139del cause altered protein conformation and thus slower migration in the SDS-PAGE gel [35]. Nomenclature
of the mutations in relation to other figures: p.Glu2431Lys = ex54m, p.Arg2478_Asp2512del = ex55del, p.Val3924_Asn3929del = ex78m,
p.Ser6366Ile = ex122m, p.Thr7382Pro = ex151m. Abbreviations: Tmod, tropomodulin; M1-M8, M163-M176, M177-M185 simple repeats;
S1R1-S1R7, S22R1-S22R7, super repeats of seven simple repeats; Ser, Serine-rich domain, SH3, Src homology domain.
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tension of 10 minutes at 72°C. The primers used for
nebulin exon amplifications and in vitro mutagenesis are
summarized in Table 2.Ethics approval
The project as a whole was approved by the ethics com-
mittee of Children’s Hospital, University of Helsinki,
Helsinki, Finland. The VL muscle was obtained from an
Table 1 NM-causing NEB mutations included in the study
Fragment Mutations in cDNAa Altered protein site Disease Reference
Neb ex53-57 (super repeat 9)
in figures ex54m
c.7291G > A p.Glu2431Lys NM, mild form Lehtokari et al. [18]
Neb ex53-57 (super repeat 9)
in figures ex55del
c.7432 + 1916_7535 + 372del p.Arg2478_Asp2512del NM, severe, intermediate
and typical forms
Lehtokari et al. [18]
Neb ex 77–81 (super repeat 14)
in figures ex78del or ex78m
c.11770_11787del p.Val3924_Asn3929del NM, mild form Lehtokari et al. [18]
Neb ex 119–125 (super repeat 18)
in figures ex122m
c.19097G > T p.Ser6366Ile NM, typical form, distal
myopathy
Lehtokari et al. [18]
Neb ex 146–153 (super repeat 22)
in figures 151m
c.22144A > C p.Thr7382Pro NM, typical form, distal
myopathy
Lehtokari et al. [18],
Wallgren-Pettersson
et al. [14]
NEB, Nebulin; NM, Nemaline myopathy.
aThe site of the mutations is reported according to the coding sequence of NEB cDNA GenBank ID NM_001164507.1 and its translation, NP_001157979.1.
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ten informed consent for tissue sampling was given by
the patient. Ethical approval for this sampling was given
by the ethics committee of Tampere University Hospital,
Tampere, Finland.
In vitro mutagenesis and sequencing
QuickChange site-directed mutagenesis kit (Stratagene,
La Jolla, CA, USA) was used to introduce site-specific
point mutations or deletions into NEB cDNA fragments.
PCR reactions were performed using a supercoiled,
double-stranded DNA as template, with two synthetic
oligonucleotide primers containing the chosen mutation.Table 2 The oligonucleotide primers used for cloning the neb
Primer name 5′-
1 Ex 54-F CGC GAA TTC CAA GGC
2 Ex 54-R CCG CTC GAG ATC GCT
3 Ex 78-F2 TAC GGA TCC AAG TAC
4 Ex 78-R1 TTT CTC GAG TGC TTG G
5 Ex 122-F1 GCG GGA TCC GAG AAG
6 Ex 122-R CCG CTC GAG GAT GTT
7 Ex 151-F CGC GAA TTC AAA TTG G
8 Ex 151-R CCG CTC GAG TTT GGC T
9 Ex 54MUT-F GATGGAGTCCCTTGGGTT
10 Ex 54MUT-R GTTCTTTTCTGCCTTTAAA
11 Ex 78DEL-F CATTACCGACACTCCGGA
12 Ex 78DEL-R CTTGCTCATTGTCAGGGCA
13 Ex 122MUT-F ACTGCTGTTCAGAGTGGC
14 Ex 122MUT R TTATATTTTACCTCAATGG
15 Ex 151MUT-F TTCACGTCAAGGAAGTGC
16 Ex 151MUT R ATCACTGACATGCTTGGG
17 Ex 78DEL-F CATTACCGACACTCCGGA
18 Ex 78DEL-R CTTGCTCATTGTCAGGGCACycling conditions were as recommended in the manual,
and the primer details are given in Table 2. The purified
products were sequenced using BigDye sequencing chemis-
try (version 3.1_ and an ABI 3730 DNA Analyzer (Applied
Biosystems, Foster City, CA, USA). The sequences were
analyzed using the Sequencher 4.1 software (Gene Codes
Corporation, Ann Arbor, MI, USA).
Construction of vectors for the expression of nebulin
super repeats
Plasmid vectors for the expression of human nebulin
super repeats 14 and 18 for the analysis of exon 78 and
exon 122 were constructed by cloning digested andulin super repeats and for in vitro mutagenesis
3′ Sequence Experimental use
TAC CGA AAG CAA cDNA amplification
CTG GAG GTC ATA GGC cDNA amplification
AAG GAA GGC TAC CG cDNA amplification
AT AAT GTC GTT TTG cDNA amplification
CAG AAA GGT CAC TAC cDNA amplification
AAG CTT GCC AAC TCG cDNA amplification
AA TAC AAC AAG GCC cDNA amplification
GC CTG TGT GGC cDNA amplification
CTTTAAAGGCAGAAAAGAAC In vitro mutagenesis
GAACCCAAGGGACTCCATC In vitro mutagenesis
AATTGCCCTGACAATGAGCAAG In vitro mutagenesis
ATTTCCGGAGTGTCGGTAATG In vitro mutagenesis
ATTAATGCCATTGAGGTAAAATATAA In vitro mutagenesis
CATTAATGCCACTCTGAACAGCAGT In vitro mutagenesis
CCAAGCATGTCAGTGAT In vitro mutagenesis
CACTTCCTTGACGTGAA In vitro mutagenesis
AATTGCCCTGACAATGAGCAAG In vitro mutagenesis
ATTTCCGGAGTGTCGGTAATG In vitro mutagenesis
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sites of the pGEX4T-1 expression vector. Plasmid vectors
for the expression of super repeats 9 and 22 for the study
of exon 54 and exon 151 were constructed by cloning
digested and purified PCR products into the EcoRI/XhoI
restriction sites of the pGEX4T-1 expression vector.
Protein production in Escherichia coli
GST-nebulin fusion proteins were expressed from the
pGEX-4 T vectors in the E. coli strain BL21 (DE3) (Invi-
trogen). The proteins were expressed by selecting a single
colony and culturing in 5 ml LB supplemented with ampi-
cillin 100 μg/ml. After growing the E. coli to absorbance
of 0.5 to 0.8 at 600 nm, the cells were induced with
0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for
3 hours at 250 rpm and 27.8°C. Harvesting of cells and
batch-binding protein purifications were performed as de-
scribed in the manufacturer’s manual (Protino® Glutathione
Agarose 4B; Macherey-Nagel, Düren, Germany).
Production of wild-type and aberrant α-tropomyosin and
β-tropomyosin
The α-tropomyosin and β-tropomyosin were expressed
in a baculovirus/Sf9 system (Invitrogen) and purified ac-
cording to previously described protocols [35,36]. The
insect cells were grown at 27°C in supplemented Grace’s
Insect Medium (Invitrogen) containing 10% fetal bovine
serum (Gibco) and 1% penicillin/streptomycin (Gibco).
Actin binding
Actin binding assays were performed using the Actin
Binding Protein Biochem Kit (Cytoskeleton, Denver, CO,
USA). Nebulin super repeats (10 μg) were allowed to bind
to F-actin (40 μg) for 30 minutes at room temperature.
The samples were run in a Beckman Coulter Optima
MAX Ultracentrifuge at 60,000 rpm for 1.5 hours. The
pellet and supernatant fractions were separated and ana-
lyzed by 12% SDS-PAGE electrophoresis, and the proteins
were stained with Coomassie Blue. The pellet and super-
natant bands were quantified from three experiments
done in duplicates using the ImageJ Program (National
Institutes of Health, Bethesda, MD, USA).
GST-pull-down assay
GST-containing WTand mutant nebulin super repeats (8 μg)
bound to beads were mixed with baculovirus-produced
and purified WT α-tropomyosin, WT β-tropomyosin, and
mutant β-tropomyosin (40 μg) in 400 μl PBS in a shaker
at 4°C for 45 minutes. Samples were centrifuged at
2000 rpm (500 x g) for 5 minutes. The supernatant was
removed, and 400 μl fresh 1xPBS was added. Samples
were washed five times with centrifugation at 1500 to
2000 rpm (300 to 500 x g) for 5 minutes. The pellets were
dissolved in 20 μl Laemmli sample buffer, and analyzedby 12% SDS-PAGE electrophoresis. The proteins were
stained with Coomassie Blue. Bands of pelleted protein
were quantified using the ImageJ Program from three ex-
periments performed in duplicate.
We also tested WT nebulin super repeat binding affin-
ity to WT α-tropomyosin and β-tropomyosin at different
concentrations using GST pull-down. Nebulin super re-
peats (8 μg) were mixed with WT α-tropomyosin and
WT β-tropomyosin (7.5, 15, 30, and 60 μg).
Statistical analysis
The statistical significance of the results was calculated
using the Mann–Whitney test when comparing two
groups, and the Kruskal–Wallis test when comparing
three or more groups.
Results
We produced four WT 283 to 347 aa long nebulin super
repeats: S9 (347 aa), S14 (347 aa), S18 (283 aa), and S22
(284 aa), and five corresponding mutants (Figure 1). The
individual simple repeats (seven in each super repeat) were
of slightly different lengths in different super repeats, hence
the size difference. We compared the binding affinities of
WT protein domains with the corresponding mutants.
Nebulin super repeat 9, containing the p.Glu2431Lys
(exon 54, c.7291G > A) mutation (which is close to a pu-
tative tropomyosin-binding site), and nebulin super re-
peat 9, lacking 35 aa due to deletion of the entire exon 55
(p.Arg2478_Asp2512del, c.7431+1916_7536+ 372del), showed
weaker affinity for F-actin compared with the WT frag-
ments, but the difference was not confirmed to be statisti-
cally significant using the Kruskal–Wallis test (Figure 2).
Super repeat 18, containing the p.Ser6366Ile (exon 122,
c.19097G > T) mutation at an actin-binding site, showed
stronger actin affinity (P = 0.048, Figure 2). Super repeat
14, containing an in-frame deletion of six aa (exon 78,
p.Val3924_Asn3929del), and super repeat 22, containing
the p.Thr7382Pro (exon 151, c.22144A > C) mutation,
showed similar affinity for actin as the WT fragments
(Figure 2).
We also performed tropomyosin-binding experiments for
the super repeats using GST pull-down assays (Figure 3).
Some of the produced nebulin domains showed degraded
fragments, but these were larger in size than tropomyosin
(Figure 1B). Super repeat 9, containing the p.Glu2431Lys
mutation, showed stronger affinity for tropomyosin but
this was not confirmed to be statistically significant. Super
repeat 9, containing the in-frame deletion of exon 55
(p.Arg2478_Asp2512del), and super repeat 14, containing
the in-frame deletion p.Val3924_Asn3929del, showed
slightly, but not statistically significant, stronger affinity for
tropomyosin. Super repeat 18, containing the p.Ser6366Ile
mutation, showed similar affinity for tropomyosin as WT
fragments. The nebulin exon 151, containing super repeat
Figure 2 Mutations affect the binding of nebulin to F-actin. Nebulin protein domains were incubated with F-actin and centrifuged. Pellet
and supernatant fractions were separated, run on SDS-PAGE gels, and stained with Coomassie Blue. The relative abundance of nebulin protein in
the pellet was quantified from three independent experiments. The mean value and standard deviations from three experiments are shown in
the bar charts to the left, and gel pictures of representative experiments are shown on the right. Nebulin domains containing the mutation
p.Ser6366Ile (ex122m) showed significantly strengthened actin affinity (P = 0.048). P values were calculated using the Kruskal–Wallis test when
comparing three groups (S9) and the Mann–Whitney test when comparing two groups (S14, S18, S22). Asterisks indicate significant differences
compared with the wild-type (WT) protein.
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nificantly weaker affinity for tropomyosin compared with
the WT protein fragment (P = 0.039). Tropomyosin affin-
ities for each nebulin super repeat are shown as binding
curves (Figure 4).
We also tested the affinity of WT nebulin super re-
peats for WT and six β–tropomyosin mutants (p.Lys7-
del, p.Glu41Lys, p.Lys49del, p.Glu117Lys, p.Glu139del,
and p.Gln147Pro) using GST-pull-down assays. Nebulin
super repeat 18 containing the WT exon 122 showedFigure 3 Nebulin mutations affect binding to tropomyosin. Purified GS
α-tropomyosin and β-tropomyosin, then beads were washed and the boun
The relative intensity of bound α-tropomyosin and β-tropomyosin was qua
standard deviations from three experiments are shown in the bar charts to
on the right. Nebulin domains containing the p.Thr7382Pro (ex151m) muta
wild-type (WT) proteins (P = 0.039). P values were calculated using the Krusk
test when comparing two groups (S14, S18, S22). Asterisks indicate significantslightly weaker affinity for the β-tropomyosin p.Glu41Lys
mutant, but this was not statistically significant using the
Kruskal–Wallis test. The other mutant tropomyosins did
not show significant differences in binding affinity for WT
nebulin compared with WT tropomyosin (Figure 5).
Discussion
The WLKGIGW motif in nebulin has been proposed to
serve as a tropomyosin-binding site [21,23]. Performing
GST-pull-down assays for four WT nebulin super repeatsT-nebulin domains bound to beads were incubated with purified
d proteins run in SDS-PAGE gels, and stained with Coomassie Blue.
ntified from three independent experiments. The mean value and
the left, and gel pictures of representative experiments are shown
tion showed significantly weakened affinity for tropomyosin than
al–Wallis test when comparing three groups (S9) and the Mann–Whitney
differences compared with the WT protein.
Figure 4 Tropomyosin-nebulin binding curves. The affinity of wild-type (WT) and mutant nebulin domains to α-tropomyosin and β-tropomyosin
is shown in binding curves. The relative quantities were calculated from three independent experiments.
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showed that all four nebulin super repeats bound to
tropomyosin with high affinity. This is the first direct evi-
dence that there is a tropomyosin-binding motif in these
super repeats of nebulin (Figure 4, Figure 5). Chitose andFigure 5 Nebulin wild-type (WT) super repeat domain affinity for mu
were incubated with purified α-tropomyosin and β-tropomyosin, then bea
and stained with Coomassie Blue. The relative quantities of bound α-tropo
experiments. Six β–tropomyosin mutants (p.K7del, p.E41K, p.K49del, p.E117K
and standard deviations from three experiments are shown in the bar char
shown on the right. (A) Binding affinities of the β–tropomyosin mutants fo
mutants for nebulin super repeat S14. (C) Binding affinities of the β–tropom
the β–tropomyosin mutants for nebulin super repeat S22. No statistically si
Neb, nebulin; Tm2, β-tropomyosin; Tm3, α-tropomyosin; GST, glutathione-Sco-workers [33] used far-western blotting and whole neb-
ulin from rabbit skeletal muscle to test tropomyosin bind-
ing. They were not able to confirm any interaction
between nebulin and tropomyosin. This could be due
to lower quantities of protein or differences in testingtant tropomyosins. Purified GST-nebulin domains bound to beads
ds were washed, and bound proteins were run in SDS-PAGE gels
myosin and β-tropomyosin were calculated from three independent
, p.E139del, and p.Q147P) were included in the study. The mean values
t to the left, and gel pictures of representative experiments are
r nebulin super repeat S9. (B) Binding affinities of the β–tropomyosin
yosin mutants for nebulin super repeat S18. (D) Binding affinities of
gnificant differences in binding affinities were found. Abbreviations:
-transferase.
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smaller protein domains that can adopt the correct
α-helical conformations.
Nebulin knockout mouse models and analyses of single
muscle fibers from patients with NM caused by mutations
in NEB have provided some insights into the pathogenesis
of NM [24,34,37-41], but in vitro functional studies of
NEB mutations have not been performed previously, to
our knowledge. Furthermore, the functional effects of
NEB missense mutations have not been addressed to date.
Recent studies have shown that patients with NM
caused by mutations in NEB may have markedly lower
levels of nebulin protein in their muscles than healthy
individuals, leading to lower calcium sensitivity of force
generation [37,39,41]. A lower abundance of nebulin has
been associated with the in-frame deletion of exon 55
(p.Arg2478_Asp2512del) included in the present study,
as well as with frameshift and splice-site mutations in
NEB [39,41]. It has been suggested that the vulnerability
of mutant nebulin to proteolysis is due to a mismatch
between nebulin and its actin-binding sites [38]. The re-
sults of our nebulin-actin binding studies support this
suggestion, as the super repeat lacking 35 aa encoded by
exon 55 (S9) showed weakened actin affinity, although
the difference was not statistically significant. The 35 aa
deletion does not span the tropomyosin-binding site in
super repeat 9 (Figure 1A), and super repeat S9 showed
slightly, but not statistically significantly, stronger bind-
ing to tropomyosin (Figure 3). The effect may be more
pronounced in vivo, when the tropomyosin-binding site
periodicity of 235 to 240 aa is disrupted by the deletion,
and the head-to-tail binding of tropomyosin dimers to
the thin filament might thus be impaired [18].
Interestingly, nebulin super repeat S9 containing the p.
Glu2431Lys mutation, which is close to a tropomyosin-
binding site (Figure 1A) showed weakened actin affinity
(Figure 2), but also stronger affinity for tropomyosin
(Figure 3). These differences were not shown to be sta-
tistically significant. This mutation was identified in a
patient with a mild form of NM, who is compound het-
erozygous for the p.Glu2431Lys mutation and a frame-
shift mutation in exon 55 (Lehtokari et al., manuscript
submitted). Stronger tropomyosin affinity may impair
the movement of nebulin in concert with tropomyosin
on the actin filament during muscle contraction. Incom-
plete movement of tropomyosin on the actin filament,
resulting in disrupted myosin cross-bridge cycling kinet-
ics and subsequent muscle weakness, has been described
in muscle fibers from a patient with NM who was com-
pound heterozygous for two splice-site mutations in
NEB. The mutations resulted in skipping of exons 3 and
22. In that patient, the abundance of nebulin in muscle
was only slightly lower than normal, and the calcium
sensitivity of force production was maintained [40].The missense mutations p.Ser6366Ile in super repeat
S18 and p.Thr7382Pro in S22 are founder mutations in
the Finnish population, and had been discovered in com-
pound heterozygous form, together with a truncating
mutation (frameshift or nonsense), to cause NM, and in
a homozygous form to cause distal myopathy without
nemaline bodies [14,18]. Interestingly, the p.Ser6366Ile
mutation significantly strengthened the actin affinity of
super repeat S18 (Figure 2). The strengthened actin affin-
ity may have an impact on actin-myosin interaction
during muscle contraction, considering that one nebulin-
binding site on actin is in close proximity to the strong
binding site for myosin on actin during muscle contrac-
tion, and that this site is blocked by tropomyosin in re-
laxed muscle [32]. The p.Thr7382Pro mutation did not
affect actin affinity, but significantly weakened the
tropomyosin affinity of super repeat S22 (Figure 3), al-
though the mutated amino acid is much closer to an
actin-binding site than to the tropomyosin-binding site
(Figure 1A). Super repeat S22 is the last super repeat be-
fore the C-terminal simple repeat region of nebulin, and
it also contains the last predicted tropomyosin-binding
site in nebulin [42].
The in-frame deletion of six aa (p.Val3924_Asn3929del)
in super repeat S14 had no effect on actin or tropomyosin
binding. This deletion does not reside in a known binding
site. A few small (1 to 5 aa) in-frame deletions and inser-
tions in NEB are listed in the Exome Variant Server (EVS)
[43], compiling exome sequencing data of healthy individ-
uals, as well as individuals with hypertension, and heart
and lung disease. To our knowledge, no patients with skel-
etal muscle disease are included in the EVS study cohorts.
Of note, some individuals in the EVS are homozygous
for the in-frame deletions, indicating that at least some
small in-frame deletions in NEB are non-pathogenic. The
p.Val3924_Asn3929del in-frame deletion in our study (not
present in the EVS) is the only small in-frame deletion
we detected in our large series of patients with NM. The
patient is compound heterozygous for p.Val3924_Asn3929-
del and a large (approximately 30 kb) duplication in NEB
(unpublished results). The pathogenicity of both mutations
remains to be established.
We also tested the affinity of six β–tropomyosin mu-
tants (p.Lys7del, p.Glu41Lys, p.Lys49del, p.Glu117Lys,
p.Glu139del, and p.Gln147Pro) for WT nebulin super
repeats using the GST pull-down assay. The tropomy-
osin p.Glu41Lys mutant showed a slightly weakened af-
finity for nebulin super repeat S18, which was not
statistically significant, but not for the other super re-
peats. The p.Glu41Lys substitution is in the non-actin-
binding β-zone of β-tropomyosin and has been shown to
cause low Ca2+ sensitivity by in vitro motility assays [35].
The other tropomyosin mutations, except p.Glu117Lys,
are in or close to the tropomyosin-actin-binding site at
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did not show significant changes in binding affinity for
WT nebulin super repeats compared with WT proteins
(Figure 5).
Conclusions
Our results demonstrate actin-nebulin and tropomyosin-
nebulin interactions in vitro, and show that mutations in
nebulin and tropomyosin can alter these interactions.
Both actin and tropomyosin-binding affinity was affected
by nebulin mutations. This suggests that abnormal inter-
action between aberrant thin-filament proteins is a
pathogenetic mechanism in NM and related disorders.
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